Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

On its most recent call, Novartis (NYSE: NVS) CEO Vas Narasimhan stated, "Our focus remains, as I've guided in recent quarters, into the sub-$2 billion space to see if there are attractive methods. And when there are good deals out there, we're, of course, looking to do them."

In fact, Narasimhan has proven to be a deal maker. Here is a sampling of what Novartis has bought since he took over as CEO in February 2018.

Using the Swiss pharma CEO's $2 billion cutoff, here are three other biotech companies that we imagine could potentially be nice tuck-in acquisitions for Novartis.

Source Fool.com